Cross-link

What You Need to Know about IOST in 2022

Retrieved on: 
Tuesday, February 15, 2022
Cardano, TRON, EOS, Matrix, Ecosystem, Blockchain, Adoption, Singapore Exchange, ZhenFund, Sequoia, Traction, Collection, Solution, Interoperability, Female, Hope, Awareness, VC, Ministry of Information, Student, Non-fungible token, Music, CCID, Cross-link, Ministry, Partnership, NFT, Decentralized finance, Growth, Research, University, News, NEO, Cryptocurrency, Beauty salon, Ethereum

To welcome our user community into the exciting new year, we're creating a series of articles in collaboration with our strategic partner on what you need to know about our partner coins in the year 2022, this time with IOST.

Key Points: 
  • To welcome our user community into the exciting new year, we're creating a series of articles in collaboration with our strategic partner on what you need to know about our partner coins in the year 2022, this time with IOST.
  • As of May 2021, Moonstake has been supporting IOST staking and network resource management via strategic partnership with the IOST development team.
  • In this article, we will be interviewing our partner at IOST about what is in store for the IOST ecosystem and its user community in 2022.
  • The IOST team will be more aggressive in 2022 to onboard more emerging Dapps into the IOST ecosystem.

Glaukos Announces Executive Leadership Changes

Retrieved on: 
Monday, February 7, 2022
Surgery, Medical Devices, Health, Pharmaceutical, Optical, J. P. Morgan, Cross-link, Business, Senior, Administration, Xavier University, Retina, Growth, Head, Glaucoma surgery, Â, Brigham Young University, Research and development, Indiana University, Cornea, NicOx, Leadership, Therapy, Technology, Corporate development, Allergan, Inc., MIGS, Patient, Corporation, Publication, Mount Kelly School, CPA, Compliance, University, NYSE, Marketing, AMO, Family, CEO, Deloitte, Glaucoma, Research, Chapel Hill, SOX, GKOS, Executive, Miami University, Arthur Andersen, Information technology, Johnson & Johnson Vision, ERP, University of North Carolina at Charlotte, Pharmaceutical industry, Management, Allergan, Chemistry, Finance, Accounting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the companys future growth and strategic plans.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the companys future growth and strategic plans.
  • The following executive changes will become effective on April 1, 2022:
    Joseph Gilliam will assume the new role of President and Chief Operating Officer.
  • In his expanded role, Mr. Thurman will assume responsibility for Glaukos entire accounting, financial planning and internal audit functions and become a member of Glaukos senior leadership team.
  • Prior to Glaukos, he held increasingly responsible financial leadership positions over 20 years at Allergan, Inc., Deloitte and Arthur Andersen LLP.

Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22

Retrieved on: 
Tuesday, February 1, 2022
Surgery, Medical Devices, Health, Pharmaceutical, Optical, EST, GKOS, Cross-link, Technology, Cornea, Corporation, International, Retina, Glaucoma surgery, MIGS, Glaucoma, PST, Conference, NYSE, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2021 financial results after the market close on Tuesday, February 22, 2022.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2021 financial results after the market close on Tuesday, February 22, 2022.
  • The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 22, 2022.
  • A link to the live webcast will be available on the companys website at http://investors.glaukos.com .
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Amplify Raises $12M Investment for Life Insurance Investment Platform

Retrieved on: 
Tuesday, January 18, 2022
Thrive Market, Technology, SAN, ADSK, Personal Capital, Retirement, Greycroft, NYSE, NASDAQ, ADBE, Singing bird box, Bleacher Report, CEO, Trunk Club, GE, Health, UBER, Insurance, History, Crosslink Capital, Science and technology in Asia, Industry, TWX, Empower Retirement, Blackstone, Seed, Conversational Capital, Investment, HuffPost, ServiceMax, Policy, San Francisco Bay Area, Bank, Life insurance, Management, Anthemis, Amazon, Venmo, Weave, Cross-link, Amplification, Chime, Omniture

SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Amplify Life Insurance , a digital life insurance platform focused on helping customers build wealth through permanent life insurance, announced today it has raised $12M in Series A funding co-led by Greycroft and Crosslink Capital.

Key Points: 
  • SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Amplify Life Insurance , a digital life insurance platform focused on helping customers build wealth through permanent life insurance, announced today it has raised $12M in Series A funding co-led by Greycroft and Crosslink Capital.
  • With built-in capabilities for expedited underwriting and policy delivery, most Amplify customers are able to get a life insurance investment policy within days and without a medical exam.
  • Since launching their customer-facing platform in 2020, Amplify has been growing over 400% Y-O-Y and has helped thousands of customers with a life insurance investment plan.
  • Amplify is the first digital permanent life insurance platform offering customers direct access to products where you access tax-efficient investment returns and obtain lifelong protection.

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

Retrieved on: 
Tuesday, January 11, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Patient, Technology, Retina, Elasticity, Eye, Pilocarpine, Cornea, MIGS, SEC, NYSE, Safety, Ageing, Glaucoma surgery, GKOS, U.S. Securities and Exchange Commission, Visual acuity, Presbyopia, Dermis, Corporation, Ilut, Glaucoma, BID, Security (finance), Cross-link, Pharmaceutical industry

The company anticipates it will enroll approximately 120 presbyopic patients in the study across clinical sites in the United States.

Key Points: 
  • The company anticipates it will enroll approximately 120 presbyopic patients in the study across clinical sites in the United States.
  • The dosing of the first patient in the Phase 2 study brings us one step closer to an innovative near vision solution for the millions of patients who suffer from presbyopia.
  • We are privileged to have the opportunity to explore what GLK-302 can do for presbyopic patients in our Phase 2 trial.
  • Presbyopia usually becomes noticeable around the age of 40 and there is no proven way to stop or reverse the progression of presbyopia.

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

Retrieved on: 
Tuesday, January 11, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, DED, Patient, Technology, Retina, Eye, Pilocarpine, Inflammation, Cornea, MIGS, SEC, NYSE, Safety, Glaucoma surgery, GKOS, U.S. Securities and Exchange Commission, Eyelid, Diagnosis, Dermis, Corporation, Ilut, Glaucoma, Duane syndrome, BID, Security (finance), Cross-link, Pharmaceutical industry

The company anticipates it will enroll approximately 200 DED patients in the study across clinical sites in the United States.

Key Points: 
  • The company anticipates it will enroll approximately 200 DED patients in the study across clinical sites in the United States.
  • Additionally, approximately 20 patients with a diagnosis of DED due to Sjogrens Syndrome will also be enrolled.
  • Dry Eye Disease is a common ocular inflammation condition with high unmet clinical need, representing one of the worlds largest ophthalmic markets worldwide.
  • We are delighted to have the opportunity to explore what GLK-301 can do for DED patients in our Phase 2 trial.

Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study

Retrieved on: 
Tuesday, January 11, 2022
Research, Medical Devices, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, General Health, Pharmaceutical, Health, Science, NDA, Patient, Technology, Retina, Eye, Cornea, MIGS, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Appetite, NYSE, Safety, Clinician Administered PTSD Scale, OAG, Glaucoma surgery, GKOS, IND, U.S. Securities and Exchange Commission, Travoprost, Timolol, Cross-link, IOP, Corporation, Food, Glaucoma, FDA, BID, Intraocular pressure, Idose, Security (finance), Ocular hypertension, Pharmaceutical industry, Risk management

The currently reported Phase 2b results are based on an analysis conducted at 36 months for all 154 subjects randomized into the trial, with 51, 54 and 49 subjects randomized to iDose TR fast-release arm, iDose TR slow-release arm and timolol active comparator arm, respectively.

Key Points: 
  • The currently reported Phase 2b results are based on an analysis conducted at 36 months for all 154 subjects randomized into the trial, with 51, 54 and 49 subjects randomized to iDose TR fast-release arm, iDose TR slow-release arm and timolol active comparator arm, respectively.
  • Overall, iDose TR subjects performed similarly to timolol subjects at 36 months in terms of mean IOP reductions with fewer topical medications versus timolol.
  • On June 10, 2021, Glaukos announced the completion of patient enrollment and randomization in its ongoing Phase 3 clinical program for iDose TR.
  • The 12-month iDose TR Phase 3 trial results are expected to support Glaukos targeted NDA submission in 2022 and FDA approval for iDose TR in 2023.

Glaukos Announces FDA 510(k) Clearance of iPRIME™

Retrieved on: 
Thursday, January 6, 2022
FDA, Medical Devices, Health, Pharmaceutical, Optical, Corporation, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, NYSE, Physician, GKOS, Glaucoma surgery, Cross-link, U.S. Securities and Exchange Commission, Security (finance), Cornea, SEC, FDA, Glaucoma, MIGS, Technology, Retina, Seven Group Holdings, Trabecula, Pharmaceutical industry

We are thrilled to announce this clearance as we believe iPRIME will be another important tool that supports the needs of physicians and patients, said Thomas Burns, Glaukos president and chief executive officer.

Key Points: 
  • We are thrilled to announce this clearance as we believe iPRIME will be another important tool that supports the needs of physicians and patients, said Thomas Burns, Glaukos president and chief executive officer.
  • This technology further expands Glaukos broad portfolio of innovative ophthalmic solutions and is consistent with our longstanding position on the value of truly minimally-invasive therapy.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 29, 2021
Surgery, Medical Devices, Health, Pharmaceutical, Optical, GKOS, Retina, Technology, NYSE, Cornea, Cross-link, Glaucoma, Glaucoma surgery, Corporation, MIGS, Conference, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.
  • Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Professional Tax Software Comparison Chart Gets Fresh Reboot By UltimateTax For the 2022 Tax Season

Retrieved on: 
Tuesday, December 28, 2021
Online, CCH, Chart, ATX, Efficiency, Software, Intuit, Cross-link, TaxAct, TaxSlayer, Bookkeeping, Online shopping

MUSCATINE, Iowa, Dec. 28, 2021 /PRNewswire/ -- UltimateTax Online has unveiled a new update of its industry-standard comparison chart for professional tax software .

Key Points: 
  • MUSCATINE, Iowa, Dec. 28, 2021 /PRNewswire/ -- UltimateTax Online has unveiled a new update of its industry-standard comparison chart for professional tax software .
  • Professional tax software has the capacity to process a high volume of tax returns for a tax preparation business.
  • The 2021 update of the UltimateTax Online chart will guide software purchase decisions as tax offices look ahead to the 2022 tax season.
  • The 2021 professional tax software comparison chart provides a helpful starting point for the preparer researching professional tax software solutions prior to making a key business purchase.